Results 131 to 140 of about 31,601 (273)

PSY55 Entry and Access Expectation for Biosimilars in the United States [PDF]

, 2012
Eric Schwartz, A.J. Gould
openalex   +1 more source

The eyes of the beholder: Perceived barriers to successful drug repurposing

British Journal of Pharmacology, Volume 183, Issue 2, Page 219-233, January 2026.
Despite tremendous advances in new drug development over recent decades, the medical needs of an ever increasing and ageing global population are still significantly unmet. Drug repurposing (DR)—finding new therapeutic uses for existing medicinal substances and products—offers a promising strategy by potentially reducing development time, costs and ...
Zsuzsanna Ida Petykó, Dalma Hosszú, Marcell Csanádi, Kristóf Gyöngyösi, George Dennis Obeng, David Ameyaw, Tamás István Dóczi, Zoltán Kaló, Donald C. Lo, Helene G. van der Meer, Pan Pantziarka, András Inotai   +11 more
wiley   +1 more source

Patent and Regulatory Landscape of Biosimilars in the United States and Europe: Implications for Advancing the Domestic Biosimilar Industry with a Focus on Anti-TNF-α Biopharmaceuticals

Journal of Intellectual Property
Biopharmaceuticals exhibit excellent therapeutic efficacy; however, their high cost remains a significant limitation. The introduction of biosimilars is expected to enhance market competition and reduce biopharmaceutical prices.
Tae-Kwon Kim, Tai-Hyun Kang
doaj   +1 more source

S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: Treatment recommendations and monitoring

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 1, Page 122-137, January 2026.
Summary This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies. The recommendations are based on the current Cochrane network meta‐analysis, the results of which are also summarized.
Alexander Nast, Andreas Altenburg, Matthias Augustin, Frank Bachmann, Wolf‐Henning Boehncke, Markus Cornberg, Hilte Geerdes‐Fenge, Brit Häcker, Peter Härle, Joachim Klaus, Michaela Köhm, Arno Köllner, Ulrich Mrowietz, Hans‐Michael Ockenfels, Antonia Pennitz, Sandra Philipp, Thomas Richter, Thomas Rosenbach, Tom Schaberg, Martin Schlaeger, Gerhard Schmid‐Ott, Michael Sebastian, Karisa Thölken, Ralph von Kiedrowski, Uwe Willuhn, Christoph Zeyen   +25 more
wiley   +1 more source

Biosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines

Journal of Pharmaceutical Policy and Practice, 2015
Maarten Van Baelen
doaj   +1 more source

FRI0200 Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy [PDF]

, 2017
Lieke Tweehuysen, VJB Huiskes, B. van den Bemt, F. van den Hoogen, Alfons A den Broeder   +4 more
openalex   +1 more source

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open‐label, phase 3 study

Journal of Diabetes Investigation, Volume 17, Issue 1, Page 42-50, January 2026.
This is a multicenter, randomized, open‐label, parallel‐group, active‐controlled, phase 3 study. The study confirmed that HS‐IDegAsp BID is non‐inferior to NN‐IDeg BID with regard to efficacy and safety in Chinese patients with T2DM who were inadequately controlled on once‐ or twice‐daily premixed or basal insulin, with or without OADs.
Leili Gao, Zhifeng Cheng, Guoqing Ma, Xiaojun Cai, Xiaoyun Wang, Yibing Lu, Ziling Li, Wei Li, Shuping Zhao, Xuefeng Li, Chengwei Song, Yunming Gao, Jianlin Geng, Haiyan Cao, Jingfang Sun, Linong Ji   +15 more
wiley   +1 more source

Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review [PDF]

, 2018
Xia Hu, Lei Zhang, Yanhu Dong, Chao Dong, Jikang Jiang, Weiguo Gao   +5 more
openalex   +1 more source

AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY) [PDF]

, 2023
O. Hagege, Thierry Lequerré, Christian Marcelli, R. Varin, D. Alcaix, Anne‐Joëlle Weber, Sorina‐Dana Mihailescu, E. Duhamel, O. Vittecoq   +8 more
openalex   +1 more source

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]

, 2019
BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie, Dulai, Parambir S, Lasch, Karen, Osterman, Mark T, Riaz, Faisal, Sandborn, William J   +5 more
core